Tags: news

Athens, 28/07/2022 TIKUN Europethe largest pharmaceutical company in the medical cannabis industry in Europe, pioneer in the research, development and production of medicinal cannabis products worldwide, welcomed the first mother plants from Israel, for the purpose of starting the cultivation in the company’s facility at Korinthos. The transportation of the mother plants took place on Friday, July 22nd and was carried out by Skyserv Ground Handling Services at Athens International Airport, Eleftherios Venizelos, in the presence of company’s executives.

The shipment of the plants was made in specially designed containers under controlled environment ensuring the best possible conditions throughout the transportation from Israel to their final destination. The plants, after the clearance from the competent authorities, were immediately transferred to the company’s production unit at Korinthos, in order to initiate the transplantation process. The company aims in the immediate initiation of cultivation in the vertically integrated greenhouse unit, with an area of 21,000 m² and an annual production capacity, reaching in full growth, the quantity of 10 tons of dry flower. The plants received will be used for propagation under strict protocols that will ensure the preservation of the unique characteristics of the mother plants to the future generations. The facility is expected to reach its full capacity levels gradually in the near future, to deliver a wide variety of finished medical cannabis dosage forms.

TIKUN Europe’s greenhouse and production units are designed to comply with the GACP / EU-GMP standards, which ensure high quality and safety complying with the national legislation for the cultivation and processing of medical cannabis. TIKUN Europe holds all the necessary licenses and certifications in order for its operation to be carried out with absolute responsibility and respect for the environment and the local community.

The Nikos Beis CEO ofTIKUN Europe said: “We welcome the first mother plants to our facilities in Greece. Their arrival marks the beginning of production at the factory in Korinthos, which takes us one step closer to the realization of our commitment. Our factory, being the largest pharmaceutical facility in its industry in Europe, is committed to creating innovative, high-quality medical cannabis products. A new era is beginning for our country with the operation of our Tikun Europe facility, paving the way for Greece to become one of the main players in the field of production and export of medical cannabis products”.

The Dimitris Giannopoulos, COO & Vice President of the Board of TIKUN Europe, stated: “After completing the construction of our production facility in Korinthos, today signifies another important milestone, that brings us one step closer to the beginning of cultivation of medical cannabis plants in the country. The main challenge and opportunity now become the development and production of a complete portfolio of high quality finished medical cannabis products to meet the needs of patients in Greece and in Europe”.

. Martha Georgila, Commercial Director of Skyserv Ground Handling Services, stated: "We are very happy that TIKUN Europe trusted Skyserv to implement the first transport of mother plants in Greece. Following all transportation protocols for that type of merchandises, along with the specific storage conditions that were required during their stay at the airport area, we managed to keep them intact until their departure to the company's factory in Korinthos".

Regarding TIKUN

TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.

About TIKUN Europe

TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.

With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.

TIKUN Europe’s activity is fully aligned with the Greek legislation provisions for the cultivation and processing of cannabis, aiming at the creation of pharmaceutical formulations that will be produced in a EU-GMP environment and by applying strict control standards and procedures which ensure high quality and safety.

The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD).

At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.

Media info
V+O Communication, Nasia Bourni - Tel. Contact 210 72 49 000 / 6936775484 - Email nb@vando.gr nb@vando.gr

Athens, 06/06/2021: . TIKUN Europe, the largest pharmaceutical company in the medical cannabis industry in Europe, has received a license to start the operations on its factory. The production process of the final medical cannabis products is expected in the near future.

TIKUN Europe’s factory is located in a privately owned area of 56,000 sq. m. in Corinth and is an investment of more than 30 million euros. The production facility is fully vertically integrated, having a R&D department and high-tech equipment. Tikun Europe’s factory has three distinct units: the greenhouse cultivation area, the post-harvest processing area, and the area designated for the production and packaging of finished medical cannabis products.

Also, TIKUN Europe’s factory, complies with the GACP / EU-GMP standards of the European Union and the domestic legislation for the cultivation and processing of medical cannabis, while its operation will be carried out with absolute responsibility and respect for the environment and the local community.

The new production unit was visited by the Minister of Development and Investments, Adonis Georgiadis, on Friday, June 3rd. The Minister's visit took place at a pivotal/crucial moment for the Company, following the legislation on medical cannabis and his first tour of the factory that had taken place 2 years ago. The Minister confirmed that the Government's commitment to investments has been implemented, with the plant launching the production process starting July.

The Nikos Beis CEO of TIKUN Europe said: "It was a great pleasure to welcome the operating license of our production unit, the construction of which was recently completed. The operation of the plant will start very soon, bringing us one step closer to the realization of our vision: to meet the ever-increasing demand of Greece and Europe for high quality medical cannabis products. Our factory is the largest pharmaceutical company in the specific industry in Europe and exploits the potential of our country to play a leading role in the global market for medical cannabis."

Regarding TIKUN

TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.

About TIKUN Europe

TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.

With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.

TIKUN Europe’s activity is fully aligned with the GACP/GMP principles and the provisions of Greek legislation for the cultivation and processing of medical cannabis, ensuring high product quality and safety.

The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD). 

At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.

Media Enquiries

V+O Communication, Nasia Bourni - Tel. Contact 210 72 49 000 / 6936775484 - Email nb@vando.gr nb@vando.gr

. TIKUN Europe, 1^η εταιρεία φαρμακευτική κάνναβης στην Ελλάδα, έδωσε το παρών στη 12^η Health Expo Athens, την εκδήλωση-θεσμό για τον ευρύτερο χώρο της Υγείας, η οποία πραγματοποιήθηκε δια ζώσης στις 21 και 22 Μαΐου στο Κέντρο Πολιτισμού «Ελληνικός Κόσμος» και στις 23 Μαΐου μέσω διαδικτυακής μετάδοσης.Στο περίπτερο της εταιρείας, οι επισκέπτες της έκθεσης είχαν την ευκαιρία να ενημερωθούν από τους εκπροσώπους της TIKUN Europe αναφορικά με την επιχειρηματική της δραστηριότητα, καθώς και τη νέα σειρά συμπληρωμάτων διατροφής TIKUN CBD, η οποία λανσαρίστηκε πρόσφατα στην ελληνική αγορά με το κοινό να δείχνει υψηλό ενδιαφέρον. Στην Ελλάδα είναι διαθέσιμα 5 προϊόντα της σειράς TIKUN CBD, τα οποία παράγονται σε πιστοποιημένο εργοστάσιο της Γαλλίας, με βάση καινοτόμες φόρμουλες που έχει αναπτύξει το R&D τμήμα της εταιρείας στην Ελλάδα και προσφέρουν ολιστική, φυσική ισορροπία. Η αποκλειστική διάθεση όλων των προϊόντων γίνεται μέσω του καναλιού του φαρμακείου.

Όσον αφορά στην επιχειρηματική της δραστηριότητα, η εταιρεία ενημέρωσε τους ενδιαφερόμενους σχετικά με την αποστολή και το όραμα της, η οποία προσδοκά να ανταποκριθεί στις διαρκώς αυξανόμενες ανάγκες της εγχώριας και ευρωπαϊκής αγοράς για σκευάσματα φαρμακευτικής κάνναβης και προϊόντα CBD.

H Marketing Manager της TIKUN Europe, Ντορέτα Δαρμανή, stated: «Είναι μεγάλη χαρά για εμάς η συμμετοχή σε μια τόσο σημαντική διοργάνωση, η οποία αποτελεί σημείο συνάντησης κορυφαίων εταιρειών και επαγγελματιών από τον χώρο της Υγείας. Στόχος μας είναι να συμβάλουμε στην έγκυρη ενημέρωση των Φαρμακοποιών, τόσο για τις εξελίξεις στον κλάδο της φαρμακευτικής κάνναβης, όσο και για το λανσάρισμα της νέας σειράς Tikun Live with CBD στο Ελληνικό Φαρμακείο, που εξασφαλίζει ολιστική, φυσική ισορροπία.».

Regarding TIKUN

TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.

About TIKUN Europe

TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.

With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.

TIKUN Europe’s activity is fully aligned with the GACP/GMP principles and the provisions of Greek legislation for the cultivation and processing of medical cannabis, ensuring high product quality and safety.

The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD). 

At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.

Media Enquiries

V+O Communication, Νάσια Μπουρνή, Τηλ. Επικοινωνίας 2107249000/6936775484, Email nb@vando.gr

TIKUN Europe, the first pharmaceutical company active in the field of medical cannabis in Greece, has completed the construction of its greenhouse cultivation unit, which is located at the region of ​​Corinth, in Peloponnese. The company will apply for the operations license by the end of March 2022. With an investment that is expected to exceed €40.000.000, TIKUN Europe has created a 56,000m2 state-of-the-art production site, with facilities and equipment of latest technology. The facility has three distinct units: the greenhouse cultivation area, the post-harvest processing area and the area designated for the production and packaging of finished medical cannabis products. 

The 21,000m2 greenhouse is the first unit designed to produce medical cannabis in Greece and the site where actual cultivation of medical cannabis plants will take place in the upcoming months. The plants will be used to create TIKUN Europe’s innovative and high-quality medical cannabis products. The facility has an annual production capacity of 10tons of dry flower that can be used for the production of various finished dosage forms. Plans include its possible expansion by 50%, with a subsequent production increase. 

Overall, TIKUN Europe’s greenhouse and manufacturing facility complies with EU GACP/GMP standards and local legislation for the cultivation and processing of medical cannabis.

All process steps are incorporated in the Quality System of the company, ensuring the high product quality and safety.

The company is in the process of obtaining all the necessary licenses and certifications and will operate with high responsibility and respect to the environment and the local community.

The cultivation operations are estimated to commence in April 2022. The GMP certification and the initiation of operations of the manufacturing facility is scheduled for June 2022.

TIKUN Europe is about to launch a complete range of CBD products; the TIKUN CBD range, a Holistic, Natural Balance offering, which is produced in a certified Factory in France.

Regarding TIKUN

TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.

About TIKUN Europe

TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.

With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.

TIKUN Europe’s activity is fully aligned with the GACP/GMP principles and the provisions of Greek legislation for the cultivation and processing of medical cannabis, ensuring high product quality and safety.

The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD). 

At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.

Media Enquiries

V+O Communication, Nasia Bourni - Tel. Contact 210 72 49 000 / 6936775484 - Email nb@vando.gr

Athens, 23.02.2022 TIKUN Europe, the first pharmaceutical company active in the field of medical cannabis, in Greece, announces the founding of its subsidiary company, TIKUN Europe Netherlands BV, which will be based in Amsterdam. 

The newly founded company will be responsible for the marketing,² sale and distribution of TIKUN Europe’s CBD line in the European market.

The product line which will be launched initially in the Greek market this coming Spring, introduces new, innovative CBD products developed by the «Research and Development (R&D) Department» of TIKUN Europe. This R&D unit is based in Greece and has created original CBD product formulas, manufactured in a certified factory in France, under the most rigorous quality standards.

TIKUN Europe’s activity is fully aligned with the Greek legislation provisions for the cultivation and processing of medical cannabis, aiming at the creation of pharmaceutical formulations that are produced in a GMP environment, whilst applying strict control standards and procedures to ensure high quality and safety. TIKUN Europe Netherlands BV, which is not a pharmaceutical company, will be responsible for the CBD product line.

Regarding TIKUN

TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.

About TIKUN Europe

TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.

With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.

TIKUN Europe’s activity is fully aligned with the Greek legislation provisions for the cultivation and processing of medical cannabis, aiming at the creation of pharmaceutical formulations that will be produced in a GMP environment and by applying strict control standards and procedures which ensure high quality and safety.

The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD). 

At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.

Media Enquiries

V+O Communication, Vaia Skandali (+30) 210.72.49.000 / (+30) 6936.567.731, Email vs@vando.gr vs@vando.gr

Αθήνα, 7/10/2021: Η Tikun Europe, φαρμακευτική εταιρία παραγωγής καινοτόμων φαρμακευτικών σκευασμάτων υψηλών προδιαγραφών, με έδρα την Ελλάδα και δραστηριοποίηση σε όλη την Ευρώπη, ξεκίνησε ενεργά τη συμμετοχή της στον διάλογο για την αναβάθμιση της ποιότητας ζωής των ασθενών μέσω της παρουσίας της σε σημαντικά ιατρικά συνέδρια που διοργανώνονται από έγκριτους επιστημονικούς φορείς από την Ελλάδα και το εξωτερικό.

Ο κ. Νίκος Μπέης, Διευθύνων Σύμβουλος της Tikun Europe, επεσήμανε σχετικά: «Η Tikun Europe, η παγκόσμια εταιρεία φαρμακευτικής κάνναβης ολοκληρώνει την παραγωγική της επένδυση στην Ελλάδα, με στόχευση την λειτουργία υπερσύγχρονης φαρμακευτικής μονάδας παραγωγής σε ιδιόκτητη έκταση 56.000μ 2 στην Κόρινθο. Η στήριξη συνεδρίων που ενισχύουν την εποικοδομητική συζήτηση και ενημέρωση με έγκριτους ιατρικούς επιστήμονες, για την αναβάθμιση της ποιότητας ζωής των ασθενών, είναι σημαντικός στόχος της Εταιρείας μας. Θα συνεχίσουμε να συμμετέχουμε ενεργά με στοχευμένες ενέργειες σε συνεργασία με την ιατρική
κοινότητα και τους επαγγελματίες υγείας προς όφελος των ασθενών».

Η Tikun Europe συμμετείχε στα ακόλουθα συνέδρια:

• Στο «21ο Πανελλήνιο Συνέδριο Περιοχικής Αναισθησίας, Θεραπείας Πόνου και Παρηγορικής Φροντίδας» που πραγματοποίησε η Ελληνική Εταιρεία Θεραπείας Πόνου & Παρηγορικής Φροντίδας ΠΑΡΗ.ΣΥ.Α., σε συνεργασία με την European Society of Regional Anaesthesia-Hellas ESRA HELLAS και την Α’ Αναισθησιολογική Κλινική του Πανεπιστημίου Αθηνών. Κατά τη διάρκεια του Συνεδρίου, πραγματοποιήθηκαν Ελεύθερες Ανακοινώσεις, Δορυφορικές Διαλέξεις, Ομιλίες, Live Demostration, Κλινικά Φροντιστήρια και συζητήσεις κατά τη διάρκεια των οποίων αναπτύχθηκαν θέματα όπως οι νέες κατευθυντήριες οδηγίες για τη διαχείριση του χρόνιου πόνου στο παιδί και στον έφηβο από τον Π.Ο.Υ., η διαχείριση χρόνιου πόνου στους επιζώντες από Covid 19 και πολλά άλλα.
• Στο «15 ο Συμπόσιο Νευρολογίας» που διοργανώθηκε από την Ακαδημία Νευροεπιστημών, υπό την αιγίδα του Ιατρικού Συλλόγου Ιωαννίνων, με στόχο να καλύψει όλες τις τελευταίες εξελίξεις στους περισσότερους τομείς της Νευρολογίας. Κατά τη διάρκεια του Συνεδρίου, υλοποιήθηκε τετραήμερο πρόγραμμα με Δορυφορικές διαλέξεις και Συμπόσια, διαδραστικές ενότητες, πρακτικές συνεδρίες, κλινικά φροντιστήρια και συνεδρίες αφιερωμένες στις κινητικές διαταραχές, την πολλαπλή σκλήρυνση και συναφή θέματα της Νευρολογίας.
• Στο «24ο Πανελλήνιο Συνέδριο Αναισθησιολογίας» συνεργάστηκαν δημιουργικά τα μέλη της Αναισθησιολογικής Εταιρείας, του Διοικητικού Συμβουλίου, των Επιτροπών του Συνεδρίου, αλλά και συναφών επιστημονικών εταιρειών, με την υποστήριξη της ιατροφαρμακευτικής βιομηχανίας. Στο πλαίσιο του Συνεδρίου συμμετείχαν διακεκριμένοι επιστήμονες από την Ελλάδα και το εξωτερικό και αναπτύχθηκαν θέματα όπως η αναισθησιολογία στην Ελλάδα του 2021, τα Διλήμματα κατά την περιεγχειρητική διαχείριση καρδιαγγειακού ασθενούς και πολλά άλλα.

Για την Tikun Global

Η Tikun Global είναι πρωτοπόρος εταιρεία στην Έρευνα Ανάπτυξη και παραγωγή προϊόντων
φαρμακευτικής κάνναβης παγκοσμίως. Ξεκίνησε τη δραστηριότητά της στο Ισραήλ το 2005
καθορίζοντας το Medical Cannabis Industry, με παραγωγικές μονάδες στα 5 σημεία του
πλανήτη US, Καναδά, Αυστραλία, Ασία (Ισραήλ) και Ευρώπη (Ελλάδα). Σήμερα είναι εταιρεία
ηγέτης με φαρμακευτικά σκευάσματα που έχουν βραβευθεί διεθνώς. Με πάνω από 15 χρόνια
κλινικών και εργαστηριακών μελετών και μεγάλη βάση δεδομένων με δεκάδες χιλιάδες
ασθενείς παγκοσμίως, τα καινοτόμα σκευάσματα της Tikun προσφέρουν υποστήριξη σε
σοβαρές παθήσεις όπως Καρκίνος, νόσος του Πάρκινσον, νόσος του Crohn, Αυτισμός,
Σκλήρυνση κατά πλάκας, Επιληψία κ.α.

Για την Tikun Europe

Η Tikun Europe είναι φαρμακευτική εταιρεία, η οποία αναπτύσσει, παράγει και διανέμει προϊόντα φαρμακευτικής κάνναβης, με κεντρικό στόχο τη βελτίωση της θεραπείας και της συνολικής ποιότητας ζωής των ασθενών.
Η παρουσία της Tikun στην Ευρώπη ξεκίνησε με καθετοποιημένη παραγωγική διαδικασία και
R&D, στην Ελλάδα. Η συνολική επένδυση ύψους €40εκ. αξιοποιεί τη δυναμική που έχει η
χώρα μας να εξελιχθεί σε διεθνές κέντρο παραγωγής σκευασμάτων φαρμακευτικής κάνναβης,
με το μεγαλύτερο μέρος να προορίζεται για εξαγωγές σε μεγάλες ευρωπαϊκές χώρες.
Η Tikun Europe βρίσκεται στο τελευταίο στάδιο δημιουργίας μιας state of the art φαρμακευτικής
μονάδας παραγωγής σε έκταση 56.000 m2 στην Κόρινθο, η μεγαλύτερη στην Ευρώπη, σε
υπερσύγχρονες εγκαταστάσεις και με εξοπλισμό τελευταίας τεχνολογίας.
Η παραγωγική μονάδα θα λειτουργεί με βάση αυστηρά πρότυπα ελέγχου και ποιότητας (GMP)
με στόχο τη διασφάλιση του βέλτιστου ποιοτικού αποτελέσματος, ενώ η δραστηριότητά της
είναι απολύτως ευθυγραμμισμένη με τα όσα προβλέπει η ελληνική νομοθεσία για την
καλλιέργεια και επεξεργασία κάνναβης με στόχο τη δημιουργία αξιόπιστων φαρμακευτικών
σκευασμάτων.

Media Enquiries
V+O Communication – Βάγια Σκανδάλη
Τηλ. Επικοινωνίας 210 72 49 000, 6936 567 731, Email vs@vando.gr